Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Dan Spillane who wrote (1334)	2/23/1999 10:12:00 PM
From: jttmab	Respond to of 2539

Dan, The label is more of a document. It classifies Celebrex as an NSAID with the warnings buy also shows some of the clinical data which shows lower risks. I may still have a copy of it at home; if you're interested I'll e-mail you a copy (PDF file). (Assuming I still have it.) Best Regards, Jim

To: Dan Spillane who wrote (1334)	2/23/1999 10:15:00 PM
From: Anthony Wong	Respond to of 2539

On using Celebrex in treatment of colon cancer and alzheimer's, initial study results seem encouraging: We have had a very active program in the research area, the preclinical animal model area, the results of which supported the notion that a drug such as Celebrex, a selective COX-2 inhibitor, might have some utility there. And we're just in the process of completing our first clinical trial in a patient population that is highly susceptible to developing colon polyps. We will know the results of that study fairly soon. Assuming the outcome will be positive, we'll be potentially moving into other areas of colon polyp prevention. We should know, probably by the end of the year, whether or not the concept of using Celebrex in the treatment of Alzheimer's has some merit. And if it does, that would clearly be another important advance and potential use of this class of drugs.

To: Dan Spillane who wrote (1334)	2/23/1999 10:21:00 PM
From: Anthony Wong	Respond to of 2539

13 companies own 80% of GM patents This is London February 23, 1999 by Jo Revill Health Correspondent More than 80 per cent of the patents covering genetically modified foods and their technology are held by a small number of companies, it emerged today. The ownership of the food chain came under fresh scrutiny as a major public debate opened in London this morning on the patenting of genetic information, encompassing both GM foods and human cloning. A computer search of 1,608 patents covering GM food technology reveals that 1,296 belong to only 13 commercial organisations. A further 256 belong to academic institutes worldwide, and 48 more belong to US government bodies. Patenting the science which governs the production of foods has become extremely important to companies which invest millions of pounds into the research. Five of the top 20 organisations with patents on transgenic plants and crop improvement using DNA technology are held by European organisations, two by Japanese firms, and the remaining 13 are based in the US. The figures were released by Der-went Information, which is sponsoring today's debate. The firm sells information to companies in a bid to highlight the role of non-profit making academic institutions. However, its managers refused to divulge the names of the companies holding the patents - or how many patents were held by Monsanto, the £5billion US company at the eye of the storm over so-called Frankenstein foods. One of those speaking out at the debate against the way patents are being used to generate profit is Labour MP Alan Simpson. The debate, chaired by Dame Fiona Caldicott of Oxford University, is being held on the second anniversary of the cloning of Dolly the sheep. © Associated Newspapers Ltd., 23 February 1999 thisislondon.co.uk